Written Grounds -Patents & SPCs
Ex-parte hearing decisions relating to patents, SPCs and SPC Extensions
| SPC No. | Product | Applicant | Decision Date |
| 2018/010 | Cladribine (MAVENCLAD) | Merck Serono S.A. | 08/10/2025 |
| 2015/043 | Safinamide for use in combination with levodopa/PDI, and optionally with other PD medicinal products, for the treatment of Parkinson's Disease | Newron Pharmaceuticals S.p.A | 14/05/2024 |
| 2014/038 | Dapagliflozin and Metformin (XIGDUO) | AstraZeneca AB | 24/05/2021 |
| 2017/035 | Talimogene Iaherparepvec (IMLYGIC) | Georgetown University | 12/04/2021 |
| 2019/010 | Binimetinib and Encorafenib (MEKTOVI/BRAFTOVI) | Array BioPharma Inc | 12/03/2021 |
| 2017/044 | Obinutuzumab and Bendamustine (GAZYVARO) | Roche Glycart AG | 19/01/2021 |
| 2009/040 | Prucalopride (RESOLOR) | Shire International GmbH | 23/08/2019 |
| 2013/035 | Insulin degludec and Insulin aspart (RYZODEG) | Novo Nordisk A/S | 14/01/2019 |
| 2014/050 | Ezetimibe and Rosuvastatin (VIAZET) | Merck Sharp & Dohme Corp. | 03/08/2017 |
| 1996/028 | Losartan potassium (COZAAR) | E.I. Du Pont De Nemours & Company | 23/09/2009 |
| 1999/002 | Valsartan (CO-DIOVAN) | Novartis AG | 10/03/2005 |
Patents Act, 1992
| No. | Title | Applicant | Opponent |
| n/a | n/a | n/a | n/a |